Open Access. Powered by Scholars. Published by Universities.®
Pharmacy and Pharmaceutical Sciences Commons™
Open Access. Powered by Scholars. Published by Universities.®
University of Nebraska - Lincoln
Department of Chemical and Biomolecular Engineering: Theses and Student Research
Articles 1 - 1 of 1
Full-Text Articles in Pharmacy and Pharmaceutical Sciences
Production Of Recombinant Human Coagulation Factor Ix By Transgenic Pig, Weijie Xu
Production Of Recombinant Human Coagulation Factor Ix By Transgenic Pig, Weijie Xu
Department of Chemical and Biomolecular Engineering: Theses and Student Research
Hemophilia B is the congenital bleeding disorder caused by deficiency in functional coagulation factor IX (FIX) and about 28,000 patients worldwide in 2012. And current treatment is restricted to protein-replacement therapy, which required FIX concentrates for patients’ life-time. Approximately 1 billion units FIX were consumed in 2012. However, still about 70-80% patients, mostly in developing countries, received inadequate or no treatment because of the unavailable and/or unaffordable FIX concentrates. Considering safety reasons, e.g. transmission of blood-borne diseases, the recombinant human FIX (rFIX) is recommended other than the plasma-derived FIX. However, only one rFIX is currently available on the market. The …